<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067795</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5181</org_study_id>
    <nct_id>NCT00067795</nct_id>
  </id_info>
  <brief_title>Evaluating Immune Function Tests in People With HIV</brief_title>
  <official_title>HIV Antigen-Specific Immune Responses - A Comparison of Alternative In Vitro Assays From Subjects Characterized as Either &quot;Stable HAART&quot; or &quot;Efficient Immune Control&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Some people's immune systems are able to control HIV infection without anti-HIV drugs. Other&#xD;
      people with HIV must take drugs to prevent the virus from destroying their immune systems.&#xD;
      There are many different laboratory tests that measure immune function in people with HIV.&#xD;
      This study will compare some of these tests to see if they consistently measure differences&#xD;
      between people who control the HIV without anti-HIV drugs and those who must take drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficiency of the immune response to HIV antigens is the critical feature that allows&#xD;
      some individuals with chronic HIV infection to maintain low level viremia (less than 3000&#xD;
      copies/ml). The fundamental measurement of this response is the steady state level of viremia&#xD;
      in the absence of antiretroviral drugs. However, using this clinical endpoint in vaccine and&#xD;
      drug trials is time-consuming. Several laboratory assays of HIV T cell function have been&#xD;
      developed to measure the key characteristics of an efficient immune response. This study will&#xD;
      evaluate these assays in two distinct patient populations.&#xD;
&#xD;
      Two patient cohorts will be followed in this study. Cohort A will enroll patients who are&#xD;
      stable on highly active antiretroviral therapy (HAART). These patients will have been on the&#xD;
      same HAART regimen for at least 9 months prior to study entry. Cohort B will enroll patients&#xD;
      with chronic HIV infection and efficient immune control. These patients will have not been on&#xD;
      any antiretroviral drugs for at least 6 months and will have viral loads less than 3,000&#xD;
      copies/ml. Participants in both cohorts will have blood drawn at study entry and Weeks 12 and&#xD;
      24. Blood samples will be used for CD4/CD8 cell count, plasma HIV-1 RNA, and immunologic&#xD;
      assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>54</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Cohorts A and B:&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  CD4 cell count &gt; 300 cells/mm3 within 60 days prior to study entry&#xD;
&#xD;
          -  Negative pregnancy test within 14 days of starting study&#xD;
&#xD;
          -  Agree to use acceptable methods of contraception while in study&#xD;
&#xD;
        Inclusion Criteria for Cohort A (Stable HAART) Only:&#xD;
&#xD;
          -  Stable HAART regimen, defined as the suppression of viral load to undetectable levels,&#xD;
             for at least 9 months prior to study entry&#xD;
&#xD;
          -  Viral load &lt; 75 copies/ml on at least three occasions within 9 months prior to study&#xD;
             entry, with at least one of these values obtained between 6 and 9 months prior to&#xD;
             study entry&#xD;
&#xD;
          -  No single viral load &gt;= 75 copies/ml within 9 months prior to study entry&#xD;
&#xD;
        Inclusion Criteria for Cohort B (Efficient Immune Control) Only:&#xD;
&#xD;
          -  Not taking any antiretroviral drugs for at least 6 months prior to study entry&#xD;
&#xD;
          -  Meets study definition of efficient immune control (generally HIV-1 viral load &lt; 3,000&#xD;
             copies/ml, with some exceptions)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements&#xD;
&#xD;
          -  History of an AIDS-defining opportunistic infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Pat Bucy, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35924-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacremento</city>
        <state>California</state>
        <zip>95814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian/St. Lukes</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1485</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Bucy RP, Kilby JM. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics? AIDS. 2001 Feb;15 Suppl 2:S36-42. Review.</citation>
    <PMID>11424975</PMID>
  </reference>
  <reference>
    <citation>Bucy RP. Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. AIDS Res Hum Retroviruses. 1999 Feb 10;15(3):223-7.</citation>
    <PMID>10052752</PMID>
  </reference>
  <reference>
    <citation>Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995 Jan 26;332(4):209-16.</citation>
    <PMID>7808486</PMID>
  </reference>
  <results_reference>
    <citation>Macatangay BJ, Zheng L, Rinaldo CR, Landay AL, Pollard RB, Pahwa S, Lederman MM, Bucy RP. Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol. 2010 Sep;17(9):1452-9. doi: 10.1128/CVI.00498-09. Epub 2010 Jul 14.</citation>
    <PMID>20631337</PMID>
  </results_reference>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>August 27, 2003</study_first_submitted>
  <study_first_submitted_qc>August 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2003</study_first_posted>
  <last_update_submitted>November 19, 2010</last_update_submitted>
  <last_update_submitted_qc>November 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2010</last_update_posted>
  <keyword>Treatment Experienced</keyword>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>HIV Antigens</keyword>
  <keyword>Cohort Studies</keyword>
  <keyword>Immunity, Cellular</keyword>
  <keyword>T-Lymphocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

